Fungal Infection, Vascular Grafting
Conditions
Keywords
vascular graft infection, vascular endograft infection, fungi, Candida
Brief summary
Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Best therapeutic management is unknown. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France over a 10 year's period in order to describe their epidemiology, clinical features, therapeutic management and outcomes. Focusing on Candida spp. VGEIs, we aim to determine prognosis factors associated with therapeutic management
Detailed description
Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Candida spp. is the most frequent fungal agent. Main risk factor is prostheto-digestive fistula. Best therapeutic management is unknown. The aim of FUNGIVAS study is to describe epidemiology, clinical features, therapeutic management and outcomes of fungal VGEIs and determine prognosis factors associated with therapeutic management. This study retrospectively gathers fungal VGEIs from 12 university hospital centers in France from January 2013 to January 2023. Patients will be identified from mycology laboratories that have diagnosed the fungal infection on a vascular sample. Demographic, clinical, biological, imaging and outcome data will be collected using a secure and anonymous questionnaire
Interventions
OTHERepidemiology and medical treatment strategies
Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023
Sponsors
University Hospital, Bordeaux
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥ 18 years old with diagnosis of vascular graft and endograft infections (VGEI) in accordance to MAGIC criteria with diagnosis of proven invasive fungal infection according to EORTC criteria. * No opposition to re-use data.
Exclusion criteria
* Patient previously treated for fungal VGEI * Patient with suspected VGEI diagnosis based solely on prosthesis implantation in an infected site * Poor understanding of French. * Patient under legal protection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of mortality | Year 1 | Rate of all-cause mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of mortality | Month 1 | Rate of all-cause mortality |
| Fungal vascular graft and endograft infections-related mortality | Month 1, Year 1 | Fungal vascular graft and endograft infections-related mortality |
| Rate of cure | Year 1 | Rate of cure, defined as : alive and without therapeutic failure (non-control of infection requiring repeat surgery or modification of anti-infective treatment) |
| Rate of sequelae | Year 1 | Rate of sequelae |
Countries
France
Contacts
Primary ContactMathilde Puges, MD
Backup ContactCarole Vignals, MD
Outcome results
None listed